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Abstract 
In the last few years Mesoporous Silica Nanoparticles (MSNs) have gained the attention of the 
nanomedicine research community, especially for the potential treatment of cancer. Although 
this topic has been reviewed before, periodic updates on such a hot topic are necessary due to 
the dynamic character of this field. The reasons that make MSNs so attractive for designing 
controlled drug delivery systems lie beneath their physico-chemical stability, easy 
functionalisation, low toxicity and their great loading capacity of many different types of 
therapeutic agents. The present brief overview tries to cover some of the recent findings on 
stimuli-responsive mesoporous silica nanocarriers together with the efforts to design targeted 
nanosystems using that platform. The versatility of those smart nanocarriers has promoted 
them as very promising candidates to be used in the clinic in the near future to overcome 
some of the pitfalls of conventional medicine.   
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1. Introduction 
Recent advances in Nanotechnology have provided a totally new arsenal to modern medicine 
in the last few years, giving birth to the so-called Nanomedicine [1,2]. This new biomedical 
area is inspiring more specific and efficient treatments towards complex diseases such as 
cancer [3]. Among that new armoury, nanoparticles for drug delivery can be employed for the 
treatment of the disease through the transport and release of therapeutic agents on a 
controlled manner, overcoming some of the typical limitations of systemic treatments. 
Nanoparticles acting as delivery vehicles of different pharmaceutical agents are predominant 
within nanomedicine, representing about the 75% of the market share of approved 
nanomedicines [4]. Some of the advantadges of using nanopartciles for drug delivery include 
the pharmacokinetic profile improve, the capacity to release therapeutic agents to specific 
tissues decreasing the side effects, and in some cases the capability to overcome certain 
biological barriers. Additionally, nanoparticles have been also used in other areas of 
nanomedicine, such as in: diagnosis, where nanopartciles allow to gain a better sensibility and 
precision; theragnostic, which is based on the combination of therapy and diagnosis and allows 
the detection and localised therapy of certain diseases together with the possibility of 
following the treatment on real time; and included in nanodevices, which can be used as 
biosensors and nanorobots. 
There are many different nanoparticles that have been proposed as nanomedicines, 
and probably the most popular are liposomes and lipid-based nanomedicines, protein 
nanoparticles, polymeric micelles and nanoparticles, polymer-drug conjugates and diverse 
inorganic nanoparticles. Among the last, Mesoporous Silica Nanoparticles (MSNs) have been 
deeply investigated as drug delivery nanocarriers because of their physico-chemical properties 
[5,6,7,8]. Those MSNs are very robust, which means that they are mechanically, thermally and 
chemically stable. They provide a great loading capacity within the porous system [9] thanks to 
their outstanding properties for the adsorption of many different types of molecules, such as 
high surface area (ca. 1000 m2/g), high pore volume (ca. 1 cm3/g) and narrow distribution of 
tunable pore diameters (2-30 nm), as it can be observed in Figure 1. Thanks to those 
properties, MSNs have been employed as drug delivery systems [10], as nanosystems for 
diagnosis [11] and nanosystems for gene transfection [12]. 
 
Figure 1. Transmission Electron Microscopy (TEM) images of MCM41 type MSNs  where the network of mesoporous 
cavi ties  ava i lable for drug loading can be observed.[7] 
Additionally, the surface of MSNs is very easy to chemically modify thanks to the 
silanol groups present on their surface, which allows designing multifunctional platforms with 
many different characteristics.  
All those features of MSNs have inspired many different research groups to host 
different therapeutic agents for transporting them to the tissue if interest [13,14,15]. MSNs 
have been observed to be endocytosed by many different mammalian cell lines [16,17,18,19] 
and the in vitro toxicology experiments have shown that MSNs are well tolerated at dosages 
lower than 100 µg/mL [20]. Additionally, in vivo biocompatibility studies of MSNs on different 
animal models have demonstrated that are well tolerated at dosages lower than 200 mg/Kg 
[21]. As those MSNs would be administered through intravenous injection to the bloodstream, 
the hemocompatibility has also been deeply investigated, showing positive results [22,23]. 
The state of the art of this first generation of MSNs with biomedical applications has 
been reviewed somewhere else.[24] However, the second generation of MSNs should be 
successfully translated from the pre-clinical proof of concept to the clinic through the 
demonstration of therapeutic value. For that purpose, the efficacy and lack of toxicity should 
be clearly presented through the appropriated pharmacokinetic and pharmacodynamics 
evaluations, together with biodistribution studies before immersing into clinical trials.  
The synthesis of MSNs is based on a modification of the Stöber method in which the 
sol-gel process is employed under very dilute conditions to obtain nanoparticles. During this 
synthetic procedure, surfactants are used as structure directing agents, so the silica precursors 
would condensate over those templates. Then, in a final step, removing the surfactant would 
lead to the network of cavities typical of these mesoporous materials.  
As it has been commented above, most of nanoparticles for drug delivery have been 
designed for the treatment of complex diseases such as cancer. In this sense, when considering 
the potential treatment of cancer, the use of nanoparticles loaded with therapeutic agents 
requires to those nanocarriers reaching the disease site and releasing the drugs there. In 
general, the drug delivery process to a solid tumour consists of 5 main steps, which are known 
as the CAPIR cascade: circulation in blood, accumulation and penetration into tumours, cellular 
internalisation, and intracellular release [25].  
Long circulation time in blood can be achieved through several ways, such as their size 
(ca. 100 nm so they will not slip out of the blood vessels during their journey into the body), or 
appropriate surface functionalisation to avoid interactions with blood components and 
reticuloendothelial system (RES). Tumour targeting can be achieved through the surface 
modification of nanoparticles, in which MSNs are virtually unbeatable in comparison to other 
nanocarriers. The reason for that is that MSNs allows carrying many different grafting 
reactions using different organic solvents, at relatively high temperatures and using multiple 
organosilanes functionalising agents. Regarding cellular internalisation and intracellular 
release, MSNs have been observed to penetrate into many different types of cells (Figure 2), 
especially when their surface is positively charged [26]. 
 
Figure 2. MSNs  (label led in green) internal i sed into mesenchymal  s tem cel l s .[26] 
Thus, the actual challenge of MSNs, and nanomedicines in general, is the selectivity 
towards certain targets into the body. The reason for that is due to the fact that conventional 
drugs rarely discriminate between healthy and cancerous cells. A possible way to overtake this 
pitfall consists on loading nanoparticles with those drugs to stay longer in circulation and 
accumulate in tumours rather than in healthy tissues. The way that those nanoparticles can 
target those tumour tissues would be discussed later in this review. 
This paper aims to review the latest findings on MSNs as drug delivery nanocarriers 
within the existing literature, and showing some of the results obtained by our research group 
in the last few years. The importance of this review may be derived from the rapidly evolving 
field of nanomedicine, in which the number of publications regarding MSNs as stimuli-
responsive drug delivery systems is constantly increasing, as shown in Figure 3. Thus, even 
though there are already many reviews on MSNs for drug delivery in the literature, this is such 
a dynamic field and things might change so fast, that regular updates are necessary to keep 
the audience informed on the last findings in the field. Thus, the present review is focused on 
the latest advances on MSNs as drug delivery agents, highlighting the development of 
responsive and targeted nanocarriers. 
 
Figure 3. Evolution of the publication of research articles on Responsive-MSNs for drug delivery. Data obtained from 
Google Scholar. 
 
2. Stimuli-Responsive MSNs 
MSNs present open porosity, which means that it might be possible to introduce therapeutic 
agents into their network of cavities, but it also might be possible for those agents to diffuse 
out when they might be in solution, obviously depending on the solvent and the selected drug. 
Therefore, it is necessary to close the pore entrances to avoid the premature release of the 
cargo during their journey through the blood vessels, which could cause several side effects 
due to the unspecific release of the drugs (Figure 4). 
 
Figure 4. Schematic representation of the unspecific release of MSNs cargo (top) and the potentia l  solutions  to 
avoid i t (bottom). 
The task of closing the pore entrances can be approached from different perspectives, 
and probably the most common is grafting stimulus sensitive gates to the pore entrances or 
covering the whole nanoparticle with a cleavable shell that would allow triggering the release 
when detached. In both cases, the final outcome would be the pore entrance closure that 
could be opened under the action of certain stimuli, both internal, which are typical from the 
treated pathology and include pH, redox potential and enzymes concentration among others; 
or external, that can be remotely applied by the clinician and include magnetic fields, 
ultrasounds, electrical fields or light (Figure 5). Previous reviews have focused on stimulus-
responsive mesoporous silica, both bulk and nanoparticles, with gate-like assemblies on pore 
openings.[27] 
   
Figure 5. Schematic representation of a capped MSN and the different stimuli, both internal and external , that can 
trigger the release of the cargo. 
 
Magnetic fields responsive MSNs 
Magnetic fields are one of the most employed stimuli in nanomedicine because they can be 
used to magnetically guide the nanoparticles when using a permanent magnetic field or to 
locally increase the internal temperature when using an alternating magnetic field. In this 
sense, superparamagnetic microspheres with an Fe3O4@SiO2 core and a mesoporous silica 
shell were produced with magnetisation and large pore volume, with great promise to be used 
as magnetically controlled drug delivery systems.[28] A similar approach was followed to 
fabricate spheres with a uniform particle diameter of ca. 270 nm with a core of magnetic 
Fe3O4/Fe and a mesoporous silica shell able to encapsulate Ibuprofen.[29] Regarding their use 
with MSNs, the most popular strategy consists on incorporating superparamagnetic iron oxide 
nanoparticles (SPIONs) of ca. 5-10 nm encapsulated within MSNs network during their 
synthesis [30,31]. Thus, the application of an alternating magnetic field to the system would 
increase the local temperature, so if the pore entrances were previously closed with a 
temperature responsive moiety, the release of the cargo would be triggered. This behaviour 
was achieved encapsulating iron oxide small nanoparticles into the network of MSNs and 
covering the surface of those MSNs with a thermosensitive polymer, poly(N-
isopropylacrylamide), to close the pore entrances to retain the cargo inside avoiding 
premature release. Additionally, a polyamine was added to the thermoresponsive polymer to 
be able to retain proteins within the shell of the nanoparticles (Figure 6). That way, it was 
possible to release two types of agents at the same time: the drug encapsulated into the pores 
(fluorescein was used as model molecule) and the protein retained into the shell (trypsin 
inhibitor was used as model protein) [32]. 
 
Figure 6. Schematic representation of a magnetic responsive MSNs  able to release two types  of agents : smal l  
molecules encapsulated into the pores and large proteins  reta ined within the shel l  of the nanoparticles .[32] 
As it can be observed in Figure 6, when applying an alternating magnetic field, the iron 
oxide nanoparticles increased the local temperature up to a point at which the conformation 
of the thermoresponsive polymer changed, so the pore entrances were opened and the 
protein and small molecules cargoes were released following different kinetics. 
Another proof of concept of this type of responsive materials consisted on 
functionalising MSNs with a single DNA strand and then loading the cargo inside the pores 
[33]. Separately, the complementary DNA sequence was attached to magnetic iron oxide 
nanoparticles of ca. 5 nm of diameter. Then, both MSNs and DNA-iron oxide nanoparticles 
were mixed to allow DNA hybridisation, as it can be observed in Figure 7. 
   
Figure 7. Schematic representation of the proof of concept MSNs  respons ive to magnetic fields  us ing DNA 
complementary s trands  to block the pore entrances .[33] 
The DNA sequence employed was selected because it presents a melting temperature 
of 47oC, so once the system was exposed to an alternating magnetic field, the iron oxide 
nanoparticles encapsulated into the MSNs network were able to increase the local 
temperature. This led to the double-stranded DNA melting with the subsequent pore aperture 
and cargo release. One of the interesting aspects of this proof of concept is that DNA linkage is 
reversible, so when the magnetic field is switched off and the system might reach physiological 
temperature, the DNA strands would hybridise again closing the pores. Then, they could be 
opened and closed again, leading to a pulsatile or on-off release mechanism.  
Same type of superparamagnetic iron oxide nanocaps have been employed in 
mesoporous silica nanorods in which the cell-produced antioxidants trigger the release of the 
cargo in the presence of an external magnetic field.[34]  
Light responsive MSNs 
The use of light with different wavelengths (ultraviolet, visible or near-infrared) for triggering 
the cargo release from MSNs has become very popular in the last few years. Some of the 
benefits of using light to trigger the release from MSNs is its easy application by the clinician 
and the focalisation to the targeted tissue, although the tissue penetrability is only few 
centimetres. Among all the possibilities, UV has been the most popular type of radiation to 
stimulate the cargo release from MSNs, because its high power is able to break bonds [35]. A 
proof of concept using this technology is presented in Figure 8, where MSNs were covered 
with a protein shell using a photosensitive linker that could be cleaved under light radiation at 
366 nm [36]. The shell covering the nanoparticles was also functionalised with transferrin, 
because it is well known that cancer cells overexpress receptors for that ligand. Thus, once the 
MSNs might be internalised into the tumour cells, the application of UV light would trigger the 
drug release, making this approach suitable for treating tumours that are accessible for light 
irradiation like the case of melanomas. 
 
Figure 8. Schematic representation of MSNs sensitive to UV l ight: the nanoparticles present high affini ty towards  
tumour cel l s  and once in the cytoplasm, the appl ication of UV l ight trigger the cargo of the MSNs.[36] 
However, UV light might be toxic because of its high Energy and also presents low 
penetration capacity. A possible alternative could be the use of visible light because it is safer 
and present higher tissue penetrability.  In fact, a proof of concept of a visible light triggered 
MSNs release system has recently been published [37].  
Ultrasound sensitive MSNs 
Ultrasound (US) is a very interesting stimuli to be used in nanomedicines because it can 
penetrate deep into living tissues without causing damage. Additionally, US is non-invasive and 
it can be focalised. Our research group has developed an US sensitive MSNs drug delivery 
system that can be activated using an US equipment that is normally used in the rehabilitation 
clinics. That system is based on decorating the surface of MSNs with a copolymer made of a 
thermosensitive and US sensitive components to close the pore entrances avoiding the 
premature release of the cargo [38]. Under the application of US, certain part of the 
copolymer cleaves, changing the hydrophobicity of the copolymer. This leads to a change of 
the conformation of the polymer at physiological temperature, opening the gates of the MSNs 
and triggering the release of the cargo, as it can be observed in Figure 9. 
 
Figure 9. Schematic representation of the US sensitive MSNs  carriers  including a  TEM micrograph of the MSNs  
decorated with the copolymer, the in vial release kinetics, and the cell internalisation and intracellular release of the 
cargo.[38] 
 In a similar approach, mesoporous silica nanoparticles have been employed to develop 
transdermal drug delivery systems that could simultaneously sense temperature and US 
stimuli.[39] The MSNs were decorated with a US sensitive polymer following the same 
procedure as the above described by our research group. 
 Ultrasound has also been proven to be very useful guiding and imaging Au 
nanoparticles-coated, perfluorohexane-encapsulated and PEGylated mesoporous silica 
nanoparticles.[40] In this approach, US irradiation effectively triggered drug release and 
excited contrast-intensified ultrasound imaging and increase ablation efficacy thanks to the US 
guidance. 
pH sensitive MSNs 
Regarding internal stimuli, which are those that employ the characteristics of the pathology to 
be treated, pH is one of the most employed to trigger the drug release from nanomedicines 
because in most tumours the pH is lower than in healthy tissues. The reason for that difference 
is the high rate of glycolysis in cancer cells, which leads to a high production of lactic acid  and 
to a reduction in the pH. That different pH has inspired many different approaches based on 
blocking the pore entrances of MSNs with different moieties that are grafted to the surface of 
the nanoparticles through responsive linkers, such as acetal linkers [41], boronate ester [42],  
ferrocenyl linkers [43], different polymers [44], aromatic amines [45], imine bonds [46], or 
calcium phosphates that are soluble at acid pH´s [47]. Our research group has recently 
developed a pH responsive MSNs based system to transport and deliver topotecan, a potent 
cytotoxic agent that commonly degrades at physiological pH, which limits its clinical use [48]. 
The surface of the topotecan loaded MSNs was decorated with a gelatin that was sensitive to 
acid pH, and then Folic Acid moieties were added to the external surface to direct the 
nanocarriers towards tumour cells that overexpress folic acid receptors (Figure 10). 
 
 
Figure 10. Schematic representation of pH sens i tive MSNs  prepared us ing a  pH sens i tive gelatin (top), TEM 
micrographs  of the as  produced systems (left) and in via l  release kinetics  under di fferent pHs .[48] 
 
Another proof of concept of MSNs sensitive to pH changes has been developed 
employing Self-Immolative Polymers (SIPs) to decorate the external surface of the 
nanoparticles [49]. The employed SIPs consist of a linear polymer based on a polyurethane 
chain with a molecule sensitive to acid pH at one of the ends. Once that molecule is cleaved 
because of acid pH, the disassembly of the polymer from head to tail would be triggered, 
yielding the initial monomers, in a process known as self-immolation. MSNs loaded with a 
model molecule were decorated with the SIP that at physiological pH was stable, so premature 
release on healthy tissues would be avoided. However, when the SIP coated MSNs system was 
exposed to acid pH, the trigger initiated the disassembly of the polymer, which provoked the 
aperture of the pore entrances and, therefore, triggering the release of the cargo only in acidic 
environments, as it can be observed in Figure 11. 
     
Figure 11. Schematic representation of the SIP-MSNs  system sens i tive to acid pH.[49] 
 Poly(acrylic acid), which is known to be pH responsive, has also been employed to 
decorate the surface of mesoporous silica nanoparticles.[50] The release of Doxorubicin from 
this platform was observed to be pH dependant, and it also increased with the decrease of the 
pH. Polymer shells composed of acrylamide and methacrylic acid coating mesoporous silica 
nanoparticles have been also employed for the design of thermo and pH dual responsive 
systems for controlled drug release.[51] 
 Nanovalves sensitive to pH have been employed for controlling the delivery of certain 
antibiotics from mesoporous silica nanoparticles, and their efficacy in treating some infections 
has been demonstrated.[52] This was an interesting approach because most of research on 
MSNs for drug delivery has been devoted to potential cancer treatment, with very few papers 
focused on the treatment of infectious diseases. This almost unexplored application might be 
fuelled up by the fact that some infectious diseases caused by pathogens reside within 
macrophages, which internalise nanoparticles more efficiently than other cells, which might 
help increasing efficacy and reducing systemic toxicity. 
MSNs loaded with prodrugs 
When considering nanoparticles for drug delivery for the potential treatment of cancer, the 
transported cargo is normally a highly cytotoxic drug, so premature release before reaching 
the tumour tissue should be avoided at all costs. This is the main motivation of stimuli-
responsive systems, but it is very difficult to design systems that do not release any of their 
cargo before reaching the target site, that is, zero-release systems, as it has been shown in 
previous examples. A possible alternative could be the use of nanocarriers able to transport 
the cytotoxic agents in an inactive state and, once they might reach the tumour tissue, activate 
those agents so the highly toxic compounds would be generated only in the targeted tissue. 
This approach has been developed employing nanoparticles able to transport a prodrug that 
would be activated by certain enzymes overexpressed by the tumour tissue [53]. However, this 
strategy is limited by the low concentration of activating enzymes in the tumour or even by the 
lack of naturally occurring enzymes necessary to activate certain prodrugs.  
MSNs have been employed to develop a system able to in situ generate cytotoxic 
drugs within tumour cells transporting both the non-toxic prodrug, loaded in the pore 
network, and the enzyme required for the drug activation, grafted to the surface of the MSNs 
[54]. The encapsulated prodrug was indol-3-acetic acid and the enzyme grafted at the surface 
of MSNs was horseradish peroxidase, that is able to transform indol-3-acetic acid into indole-3-
carbinol generating cytotoxic compounds such as hydroxyl and reactive oxygen species. The 
stability of the enzyme was ensured by coating them with a polymeric capsule (Figure 12). 
   
Figure 12. Schematic representation of MSN loaded with a prodrug and decorated with encapsulated enzymes  on 
their surface. Indol-3-acetic acid is released and activated intracellularly by the horseradish peroxidase leading to 
the production of cytotoxic compounds  to provoke cancer cel l s  death.[54] 
  Cisplatin was the first platinum-based anticancer drug and was proven to be one of the 
most potent anticancer drugs. However, its efficacy has been reduced by resistance of cancer 
cells. The use of nanocarriers able to internalise and ensure intracellular cisplatin accumulation 
results in an innovative and promising strategy to circumvent cisplatin resistance. In this sense, 
MSNs have been employed to deliver a cisplatin prodrug, together with chlorin e6, for the 
design of a combination of chemophotodynamic dual therapy against cisplatin resistant cancer 
cells.[55]   
3. Selective targeting for MSNs 
Localising nanocarriers into the specific tissues where the therapeutic agent is required is one 
of the milestones when considering MSNs for nanomedicine. That is of particular interest if 
nanocarriers are going to be used in cancer therapies to avoid side effects and damage to 
healthy cells. In fact, cancer is the pathology that is receiving most of the attention from the 
nanomedicine community, and the reason for that is the possibility of targeting the 
nanocarriers to specific tissues, both through passive and/or active targeting. 
When MSNs, and nanoparticles in general, are injected into the blood stream, they 
tend to accumulate in solid tumours thanks to the so-called enhanced permeation and 
retention (EPR) effect or passive targeting [56,57]. The reason for that lies beneath the 
abnormalities present in tumour blood vessels, that present wide interendothelial junctions, a 
great amount of phenestrations and transendothelial pores with dimensions of several 
hundred nm (Figure 13). Thus, when nanoparticles are travelling through the bloodstream, 
there is a high probability that they might extravasate through the previously mentioned 
fenestrations present in tumour vessels and accumulate into the tumour interstitium. 
Additionally, those nanoparticles already in the tumour would remain in there because of the 
ineffective lymphatic drainage that results from the fast growth of the tumour tissue.   
 
Figure 13. Schematic representation of passive targeting (left), where nanoparticles injected into the blood s tream 
preferentially accumulate in solid tumours  thanks  to their particular blood vessel  archiotectures ; and active 
targeting (right) with nanoparticles  decorated with di fferent targeting moieties . 
On the other hand, active targeting is based on the fact that some tumour cells 
overexpress certain receptors on their surface. If nanoparticles are functionalised with ligands 
with high affinity towards those receptors, the specific retention and uptake of those 
nanoparticles by cancer cells can be enhanced. This is of particular interest because tumour 
mass has been found to be a very heterogeneous tissue, composed of many different types of 
cells. Thus, it is necessary to provide nanoparticles the capacity to distinguish between tumour 
cells and the rest of the cells that might be present into the neoplastic tissue. There are many 
different approaches for decorating the surface of MSNs with certain ligands able to interact 
selectively with specific cellular receptors overexpressed in tumour cells. Some examples of 
targeting ligands grafted to MSNs are transferrin [36,58,59], epidermal growth factor [60], 
folic acid [61,62,63,64,65,66,67,68], methotrexate [69], anisamide [66], transactivator of 
transcription peptides [70,71,72], interleukin-13 peptide [73], anti-herceptin [74], anti-
epidermal growth factor receptor [75], anti-receptor tyrosine-protein kinase [76], 
metaaminobenzyl guanidine [77], RGD-type peptide [78,79,80,81,82], concanavalin A [83], 
cyclic RGD [84,85,86], anti-cell adhesion molecule 1 [87], and vascular endothelial growth 
factor [88]. However, the lack of application of those covalently targeted systems in the clinic 
might be explained by the fact that when placing MSNs in a biological environment, their 
surface would be rapidly covered by proteins, leading to the formation of a corona. The 
adsorption of those proteins would alter many surface properties of the nanoparticles, 
masking all the previous designed targeting moieties, and providing the nanoparticles with a 
totally new identity that would determine their biodistribution.   
An additional problem when approaching the treatment of cancer with nanoparticles is 
the poor penetration of those nanoparticles across the tumour mass. This is due to the 
presence of collagen in the extracellular matrix of the tumour mass, which makes it denser 
than the matrices present in healthy tissues. That high density makes even more difficult for 
the nanoparticles to penetrate into the tumour mass. A possible approach to tackle this high 
density matrix was developed decorating the surface of MSNs with collagenase, which is a 
proteolytic enzyme capable of digesting the collagen rich extracellular matrix [89]. This enzyme 
was protected with pH sensitive polymeric capsules to avoid any type of biodegradation before 
reaching the tumour tissue. Thus, under the typical acidic environments of tumours, those 
nanocapsules would be decomposed, releasing the collagenase that would digest the 
extracellular matrix of the tumour, and therefore improving the penetrability of the MSNs 
deep into the tumour mass (Figure 14).  
 
Figure 14. Schematic representation of MSNs decorated with capsules that contain collagenase. Once the capsules  
are degraded, the collagenase would digest the collagen-rich extracellular matrix of the tumour. On the right hand 
bottom corner of the figure, a  3D col lagen gel  was  prepared with HOS cel l s  seeded, and the penetration of 
fluorescently label led MSNs  on the col lagen gels  was  eva luated. [89] 
A totally different approach to selectively accumulate MSNs in tumours is based on 
using cells with migratory properties towards tumours as vehicles for those MSNs. In this 
sense, human Decidua Mesenchymal Stem Cells (DMSCs) have been successfully employed as 
carriers of nanopartciles. Those cells present very interesting characteristics, such as migration 
towards tumours both in vitro and in vivo, reducing the development of those tumours; they 
are very easy to obtain; and they represent a homogeneous population, being adult stem cells, 
which avoid any ethical concerns [90]. These DMSCs have been employed to ferry MSNs 
loaded with doxorubicin to tumour tissues [26]. The capability of those cells to migrate 
towards tumours both in vitro and in vivo was successfully evaluated, together with their 
ability to induce tumour cells death. Additionally, US responsive MSNs have also been 
internalised into those cells observing that MSNs were transported by the cells, and once in 
the tumour tissue, the application of US triggered the release of the cargo from the MSNs [91]. 
Thus, cellular transportation to specific tissues and responsive behaviour were combined at 
the same time (Figure 15), which represents a very promising platform to be used in the area 
of nanomedicine for the treatment of cancer. 
  
Figure 15. Schematic representation of DMSCs  transporting US-sens i tive MSNs  towards  tumour ti ssues .[91] 
 
4. Conclusions 
MSNs have become very promising nanocarriers to potentially treat cancer thanks to 
their outstanding properties, such as their great loading capacity, their easiness to be 
surface decorated, their robustness and their observed low toxicity. The possibility of 
designing smart nanocarriers able to respond to certain stimuli, both internal or 
external, and to selectively accumulate in determined pathological tissues have fuelled 
the interest of the nanomedicine community into those mesoporous silica materials. 
However, if translation to the clinic is aimed, it is necessary to present a proof of 
concept of efficacy and toxicity with those new approaches. After comparing the MSNs 
platforms with the standard of care, the potential advantages of those nanocarriers 
should be clearly shown employing pharmacokinetic and pharmacodynamics studies. 
Then, toxicity in real scenarios should be discarded to then ensure, through 
biodistribution studies, that MSNs reach tumour tissues. Thus, there are many-
preclinical tests that should be successfully carried out before getting involved into 
clinical trials. The sooner those experiments might be done, the sooner we might find 
MSNs involved into clinical trials and, maybe in the future, into the Clinic. 
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